What’s Next for Bio-path Holdings Inc (NASDAQ:BPTH) After Having Less Shares Shorted?

Bio-Path Holdings, Inc. (NASDAQ:BPTH) Logo

The stock of Bio-path Holdings Inc (NASDAQ:BPTH) registered a decrease of 16.63% in short interest. BPTH’s total short interest was 267,200 shares in February as published by FINRA. Its down 16.63% from 320,500 shares, reported previously. With 71,700 shares average volume, it will take short sellers 4 days to cover their BPTH’s short positions. The short interest to Bio-path Holdings Inc’s float is 2.51%.

The stock decreased 3.38% or $0.07 during the last trading session, reaching $2. About 113,215 shares traded. Bio-Path Holdings, Inc. (NASDAQ:BPTH) has declined 85.60% since February 10, 2018 and is downtrending. It has underperformed by 85.60% the S&P500.

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused antisense drug development firm in the United States. The company has market cap of $3.52 million. The firm develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid backbone modification intended to protect the DNA from destruction. It currently has negative earnings. The Company’s lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia and chronic myelogenous leukemia; and in preclinical studies for solid tumors, including breast cancer and ovarian cancer.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More notable recent Bio-Path Holdings, Inc. (NASDAQ:BPTH) news were published by: Benzinga.com which released: “52 Biggest Movers From Friday – Benzinga” on January 22, 2019, also Benzinga.com with their article: “24 Stocks Moving In Monday’s Pre-Market Session – Benzinga” published on August 27, 2018, Globenewswire.com published: “Bio-Path Holdings Reports First Quarter 2018 Financial Results – GlobeNewswire” on May 16, 2018. More interesting news about Bio-Path Holdings, Inc. (NASDAQ:BPTH) were released by: Seekingalpha.com and their article: “Bio-Path +38.6% after presentation of prexigebersen data – Seeking Alpha” published on April 18, 2018 as well as Globenewswire.com‘s news article titled: “Bio-Path Holdings Reports Third Quarter 2018 Financial Results – GlobeNewswire” with publication date: November 15, 2018.